Results 161 to 170 of about 358,200 (372)

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Insight into the electronic, optical, and thermoelectric properties of novel ternary chalcohalides: next-generation energy applications. [PDF]

RSC Adv
Khan MS, Binzowaimil AM, Stampfl C, Fakhera F, Conquest OJ, Al-Hmoud M, Aziz SM.   +6 more
europepmc   +1 more source

TREND: Xignite. FactSet Corporate Fundamentals: 5 Year Annual Income Growth Rate | Stock Symbol: AAPL | Symbol Name: Apple Inc, 11/21/2011 - 11/11/2016. Data-Planet™ Statistical Datasets by Conquest Systems, Inc. Dataset-ID: 016-005-010

, 2016
Xignite
openalex   +1 more source

Peru’s Indian Peoples and the Challenge of Spanish Conquest: Huamanga to 1640 [PDF]

, 1983
Noble David Cook
openalex   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Conquest [PDF]

International Journal for Quality in Health Care, 1996
openaire   +2 more sources

Practical strategies for achieving system change in the US: lessons and insights from the CONQUEST quality improvement programme. [PDF]

Prim Health Care Res Dev
Evans A, VanWyk J, Kerr M, Couper A, Pace WD, Tarabichi Y, Pullen R, Pollack M, Drummond MB, Ohar J, Meldrum C, Han MK, Kaplan A, Winders T, Wisnivesky J, Make B, Federman A, Carter V, Lang K, Mapel D, Hanania NA, Stolz D, Martinez FJ, Price D.   +23 more
europepmc   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Effect of chemotherapy on passenger mutations in metastatic colorectal cancer

Molecular Oncology, EarlyView.
Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...
Marium T. Siddiqui, Matthew A. Cottam, Muhammad Bilal Mirza, Keeli B. Lewis, Kristen K. Ciombor, Mary Kay Washington, Kamran Idrees   +6 more
wiley   +1 more source

Continuous Rating Scale Analytics (CoRSA): A tool for analyzing continuous and discrete data with item response theory. [PDF]

Behav Res Methods
Chou YT, Sung YT, Yang WH.
europepmc   +1 more source